Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2021; 13(1): 37-57
Published online Jan 15, 2021. doi: 10.4251/wjgo.v13.i1.37
Published online Jan 15, 2021. doi: 10.4251/wjgo.v13.i1.37
Mining The Cancer Genome Atlas database for tumor mutation burden and its clinical implications in gastric cancer
Dong-Yan Zhao, Xi-Zhen Sun, Shu-Kun Yao, Department of Gastroenterology, China-Japan Friendship Hospital, Beijing 100029, China
Dong-Yan Zhao, Xi-Zhen Sun, Shu-Kun Yao, Graduate school, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
Author contributions: Zhao DY conceived and designed the study and wrote the manuscript; Sun XZ took part in analyzing the data; Yao SK designed the study, revised the manuscript, and obtained the funding; all authors read and approved the final manuscript.
Supported by National Key Development Plan for Precision Medicine Research , No. 2017YFC0910002 .
Institutional review board statement: This study was approved by the Ethics Committee of China-Japan Friendship Hospital (No. 2018-116-K85-1).
Informed consent statement: All the data were obtained from The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/repository) database in our study. TCGA database is freely available open to the public, so there is no requirement for additional informed consent statement.
Conflict-of-interest statement: All authors report no conflicts of interest.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shu-Kun Yao, MD, PhD, Professor, Department of Gastroenterology, China-Japan Friendship Hospital, No. 2 Yinghua East Road, Chaoyang District, Beijing 100029, China. shukunyao@126.com
Received: September 17, 2020
Peer-review started: September 17, 2020
First decision: November 3, 2020
Revised: November 8, 2020
Accepted: November 28, 2020
Article in press: November 28, 2020
Published online: January 15, 2021
Peer-review started: September 17, 2020
First decision: November 3, 2020
Revised: November 8, 2020
Accepted: November 28, 2020
Article in press: November 28, 2020
Published online: January 15, 2021
Core Tip
Core Tip: Whether tumor mutation burden (TMB) is associated with a favorable prognosis remains controversial in various cancers. Accumulating evidence highlights that it is necessary to explore clinical impact of TMB in gastric cancer (GC). We defined the highest mutation load quintile (top 20%) in GC as the high-TMB group and found that high TMB values were associated with improved clinical outcomes, which might be attributed to the induction of antitumor immune responses in the microenvironment. We developed a microRNA-based signature to predict TMB values, which might serve as a surrogate biomarker for TMB in GC and aid physicians in clinical medical decision-making.